Tempest Therapeutics, Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 76/100
What the filing says
Tempest Therapeutics entered into a Purchase Agreement dated August 13, 2026 with Lincoln Park Capital Fund, LLC, permitting Lincoln Park to purchase up to $50 million in common stock at the company's discretion. Lincoln Park receives 560,356 Initial Commitment Shares immediately and 350,223 Additional Commitment Shares upon $25M in purchases. The agreement allows regular purchases (up to 80,000 shares at 97% of lowest recent price), accelerated purchases (up to 300% of regular amount at 96% VWAP), and additional accelerated purchases. The exchange cap limits issuance to 19.99% of outstanding shares (3,195,881 shares) unless stockholder approval obtained. Agreement terminates on Maturity Date (August 13, 2028) or upon full $50M purchase, whichever earlier.
Why this rating
Substantial financing commitment ($50M potential vs. $30M market cap) materially expands capital access. Dilutive but at-market pricing structure. Non-binding puts flexibility in company's hands but carries dilution risk if fully drawn.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.